Organization
Department of Gynecological Oncology
3 abstracts
Abstract
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.Org: Biometrics Department, Department of Gynecological Oncology, Sint Antonius Hospital, Department of Gynecology and Obstetrics, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Study on the efficacy and toxicity of pamiparib combined with tamoxifen in the treatment of patients with epithelial ovarian cancer with biochemical recurrence during first-line PARPi maintenance therapy.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study).Org: Sun Yat-Sen Memorial Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China,